US 12,121,583 B2
Therapeutic derivatives of interleukin-22
Kristian Sass-Ørum, Bagsvaerd (DK); Rasmus Jørgensen, Søborg (DK); Sebastian Beck Jørgensen, Bagsværd (DK); Henning Thøgersen, Bagsværd (DK); Thomas Hoeg-Jensen, Bagsværd (DK); and Michael Paolo Bastner Sandrini, Bagsværd (DK)
Assigned to Cytoki Pharma ApS, Søborg (DK)
Filed by Cytoki Pharma ApS, Søborg (DK)
Filed on Apr. 5, 2024, as Appl. No. 18/628,440.
Application 18/628,440 is a continuation of application No. 18/345,832, filed on Jun. 30, 2023.
Application 18/345,832 is a continuation of application No. 17/737,849, filed on May 5, 2022, granted, now 11,806,403, issued on Nov. 7, 2023.
Application 17/737,849 is a continuation of application No. PCT/EP2020/081523, filed on Nov. 9, 2020.
Claims priority of application No. 19207766 (EP), filed on Nov. 7, 2019.
Prior Publication US 2024/0252649 A1, Aug. 1, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/52 (2006.01); A61K 47/54 (2017.01); A61P 1/16 (2006.01); A61P 3/04 (2006.01); A61P 3/10 (2006.01); A61P 11/00 (2006.01)
CPC A61K 47/542 (2017.08) [A61P 1/16 (2018.01); A61P 3/04 (2018.01); A61P 3/10 (2018.01); A61P 11/00 (2018.01)] 6 Claims
 
1. A derivative of IL-22 comprising a fatty acid covalently attached to an IL-22 protein by a linker, wherein
(i) the IL-22 is a variant of native mature human IL-22 (hIL-22; SEQ ID NO. 1) wherein the variant comprises 1, 2, or 3 amino acid substitutions including a Cys substitution at position 1 of hIL-22;
(ii) the linker is covalently attached to the substituted Cys residue at position 1 of hIL-22;
(iii) the fatty acid has the structure HOOC—(CH2)x—CO—*, wherein x is 16 and * designates the point of attachment to the linker; and
(iv) the variant comprises a G-P-G N-terminal peptide.